Compare EPR Properties (EPR) vs Moderna, Inc. (MRNA) Price & Performance

EPR Properties trades at $54.74, up 1.22% today, with a bearish technical signal despite oversold RSI readings. The REIT reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Fundamentals show strong profitability with a 37.66% net income margin and a 6.5% dividend yield, supported by $421M in operating cash flow for 2025. Recent news highlights its appeal as a high-yield monthly dividend stock for retirees, with diversification into theme parks and fitness.

The outlook is cautiously optimistic, with a consensus price target of $65.50 implying 20% upside, though technical weakness and a projected net cash flow decline in 2026 pose risks. Investment opportunities include undervaluation relative to peers and resilient tenant performance, while risks involve interest rate sensitivity and execution of diversification strategy amid economic uncertainty.

Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.

While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.